New personalized genetic mouse model of Lesch-Nyhan syndrome for pharmacology and gene therapy by Kalmykov, V. A. et al.
New personalized genetic mouse model of Lesch-
Nyhan syndrome for pharmacology and gene therapy
Vladislav A. Kalmykov1, Pavel A. Kusov2, Maria I. Yablonskaia3, Evgeniy N. Korshunov1, Diana S. 
Korshunova1, Marina V. Kubekina1, Yuliya Yu. Silaeva1, Alexey V. Deykin1,4, Nikolay E. Lukyanov5
1 Institute of Gene Biology of the Russian Academy of Sciences, 34/5 Vavilova str., Moscow, 119334, Russia
2 Skolkovo institute of science and technology, Moscow region, the village of Skolkovo, Novaya str., 100, 143025, Russia
3 Research and Clinical Institute for Pediatrics named after Academician Yuri Veltischev of the Pirogov Russian National Research Medical 
University of the Russian Ministry of Health, 1 Ostrovityanova str., Moscow, 117997, Russia
4 Institute of General Pathology and Pathophysiology of the Russian Academy of Medical Sciences, 8 Baltiyskaya Street., Moscow, 125315
5 Yaroslavl State Medical University, Ministry of Health of Russia, 5 Revolyutsionnaya str., Yaroslavl, Russia, 150000
Corresponding author: Alexei Deykin (deikin@igb.ac.ru)
Academic editor: Mikhail Korokin  ♦  Received 8 October 2018  ♦  Accepted 6 November 2018  ♦  Published 21 December 2018
Citation: Kalmykov VA, Kusov PA, Yablonskaia MI, Korshunov EN, Korshunova DS, Kubekina MV, Silaeva YYu, Deykin AV, 
Lukyanov NE (2018) New personalized genetic mouse model of Lesch-Nyhan syndrome for pharmacology and gene therapy. 
Research Results in Pharmacology 4(4): 115–122. https://doi.org/10.3897/rrpharmacology.4.32209
Abstract
Introduction: Lesch-Nyhan syndrome is a clinical and laboratory disorder caused by X-linked disruption of the purine 
metabolism. The deletion in the HPRT1 gene leads to the disappearance of valine in the eighth position of the protein 
amino acid sequence. The disease occurs in males and is accompanied by an excess of uric acid, urate nephropathy and 
neurologic impairment.
Objective of the Study: Generation of the new personalized genetic mouse model of Lesch-Nyhan syndrome for pre-
clinical study of new approaches to the pharmacological and gene therapy
Materials and Methods: For genomic editing, the sequence was synthesized the sequence of the matrix GACCG-
GTCCCGTCATGCCGACACGCAGTCCCAGCGTGGTGAGCCAAGGGGACTCCAGCAGAGCCCCACAG was 
synthesized. For the cultivation of viable mouse embryos after microinjection, KSOM media was used. Amplification 
and sequencing was performed by the standard methods.
Results: A boy with not previously described hemizygous variant in the HPRT1 gene, was observed in our clinic. The 
mutation was the deletion of 8Val in the first exon of the HPRT1 gene. To introduce this mutation, we used the CRIS-
PR-Cas9 genomic editing system. The genetic construct for microinjections included a mixture of the vector for the 
expression of Cas9 and sgRNA (px330), as well as the matrix for homologous recombination (ssODN), in a ratio of 1 
part Cas9 to 3 parts of the ssODN matrix. Four of the 12 obtained animals were mosaic transgenes. One of 4 mice mated 
with a male from the hybrid strain CBA x C57BL/6, and descendants of F2 have already been received from this mating.
Discussion: During the creation of HPRT1 genetically modified mice, we encountered certain difficulties. First, from 
615 transplanted embryos, only 12 were able to complete full embryonic development. 9 recipients we observed abor-
tions in the later stages. These data may indicate possible violations of embryonic development in animals carrying a 
mutant copy of the HPRT1 gene.
Conclusion: In the current study, we present the results of the generation of a genetically modified mouse strain carry-
ing a deletion in the HPRT1 gene. These mice can be effectively used for the preclinical testing of new drugs aimed at 
the treatment of Lesch-Nyhan syndrome.
Copyright Kalmykov V et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
The problem of orphan (rare) diseases, despite the low pre-
valence in the population, is very important for medicine. 
It is now believed that most of these diseases are incurable. 
However, hereditary metabolic diseases, as global medical 
practice shows, are considered one of the most promising 
directions in the development of therapies. Lesch-Nyhan 
syndrome (ICD-10: E79.1; OMIM 300322; ORPHA: 510) 
is an X-linked inborn error of purine metabolism that is 
caused by mutations in the HPRT1 gene encoding the pu-
rine recycling enzyme hypoxanthine-guanine phosphori-
bosyltransferase (HPRT), which catalyzes the conversion 
of hypoxanthine to inosine monophosphate and guanine 
to guanosine monophosphate in the presence of phospho-
ribosylpyrophosphate (Harris 2018, Nguyen and Nyhan 
2016, Vargiami et al. 2016). The disease was first descri-
bed in 1964 by Nyhan W.L. and Lesch M. The prevalence 
of Lesch-Nyhan syndrome is 1-9/1 000 000, and the esti-
mated prevalence at birth is between 1/380 000 and 1/235 
000 live births. Males are generally affected, and hetero-
zygous females are carriers (usually asymptomatic) (Gar-
cía and Torres 2010). Uric acid overproduction and urate 
nephropathy in this disease can be combined with neuro-
logic impairment (Campolo González et al. 2018), which 
leads to three overlapping clinical phenotypes: (1) the 
classical form of Lesch-Nyhan disease, characterized by 
cognitive impairment, dystonia, choreoathetosis, spastici-
ty, self-injurious behavior, and urate nephropathy; (2) an 
intermediate phenotype with hyperuricemia and variable 
neurological manifestations with no self-injurious behavi-
or; and (3) hyperuricemia alone (Harris 2018). The basic 
principles of therapy include the prevention and treatment 
of urolithiasis and gout (in adults) and the correction of 
neurological manifestations. Hyperuricemia and uric acid 
nephropathy respond well to treatment with allopurinol, 
but this treatment has no effect on behavioral and neuro-
logical symptoms. However, for patients with the classic 
variant of Lesch-Nyhan syndrome, the effective therapy 
of neurological disturbances remains a task to be solved.
The intensive development of animal genetic engi-
neering methods allows for a wider consideration of the 
concept of personalized medicine. Experiments on animal 
models are becoming an indispensable stage in the precli-
nical testing of therapeutic strategies. Thus, a personalized 
model of a genetic disease makes it possible to evaluate 
the contribution of the detected mutation to the phenoty-
pe- to evaluate the potential efficacy of gene therapy.
Despite the fact that Hprt1-deficient mice models do 
not have a clinical complex characteristic of patients with 
Lesch-Nyhan syndrome, these models should be used in 
studies of brain metabolism (Bell et al. 2016) and precli-
nical studies of the effectiveness of new treatments for 
this disease, particularly of gene therapy. 
At present, the genome editing technology CRIPSR-
Cas9 (Doetschman and Georgieva 2017, Yang et al. 2017) 
allows the creation of knockout mouse models with the 
introduction of mutations in the HPRT1 gene of certain 
patients (Kato and Takada 2017, Wu et al. 2013). We con-
sider that such targeted models may be useful for the de-
velopment of gene therapy for Lesch-Nyhan syndrome.
Materials and methods
The animals and the conditions of their care have been 
described previously (Silaeva et al. 2013). Protocols for 
the induction of superovulation, obtaining fertilized eggs 
at the pronucleus stage in mice, microinjection, transplan-
tation of eggs into the oviduct of the pseudopregnant reci-
pient, and for preparing vasectomized males and recipient 
animals have been published previously (Silaeva et al. 
2013, Silaeva et al. 2018, Zvezdova et al. 2010).
We used the px330 vector (Cong et al. 2013) according 
to the protocol provided by Addgene (https://www.addge-
ne.org/crispr/zhang/).
The matrix was synthesized by the Evrogen Compa-
ny. The sequence of the matrix was GACCGGTCCCGT-
CATGCCGACACGCAGTCCCAGCGTGGTGAGC-
CAAGGGGACTCCAGCAGAGCCCCACAG
Mouse embryo culture. For the cultivation of viable 
mouse embryos after microinjection, KSOM media was 
used. The cultivation of the embryos to the blastocyst 
stage was carried out in mineral oil (Merck, USA) under 
conditions of absolute humidity at 37°C in 5% CO2.
The DNA isolation from blastocysts was performed 
according to a previously published protocol (Dimitrieva 
et al. 2016).
The DNA isolation from tissue samples was perfor-
med according to a standard protocol (Dimitrieva et al. 
2016).
Sample preparation for Sanger sequencing included 
the amplification of the gene of interest (fragment size 544 
b.p.) using the primers presented in Table 1. Amplification 
was performed under the following conditions: 95°C - 5 
min, (95°C - 30 sec, 58°C - 25 sec) - 30 cycles, 72°C - 40 
sec, 72°C - 10 min, and 4°C - storage. Then, the fragment 
was visualized on a 2% agarose gel. Further sample pre-
paration was carried out according to the protocol of the 
Evrogen Company for performing sample sequencing.
The restriction analysis of the F0 and F1 generations 
was performed based on the presence of the BstX1 res-
triction site in the wild-type HPRT1 matrix and its absen-
ce in the mutant gene (Figures 1, 2).
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Figure 1. A) – Sequencing results for F0 transgenes; B) – Restriction analysis results for F0 transgenes
Figure 2. A) – Sequencing results for F1 transgenes; B) – Restriction analysis results for F1 transgene
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Software. Analysis of the sequencing results was per-
formed using the program Peak Scanner (Thermo Fisher 
Scientific). Then, to identify matches with the mutant 
matrix and the wild-type matrix, the program Geneious 
(Biomatters Limited) was used. The protein models were 
visualized and aligned in PyMol (Schrödinger, Portland, 
OR). The analysis of the transgenic animal generation re-
sults was performed in Microsoft Excel (USA).
Results
Genetic analysis of the HPRT1 gene in our patient
Clinical case. A boy with a classic variant of Lesch-Nyhan 
syndrome was observed in our clinic. The age of the pa-
tient at the time of diagnosis was 9 years. Genetic analysis 
of the HPRT1 gene was performed by direct automatic 
sequencing of the entire coding region of the gene, inclu-
ding exon-intron boundaries. The patient had a hemizy-
gous variant in the HPRT1 gene, which has not been pre-
viously described (Table 2). The boy showed neurological 
dysfunction characterized by moderate cognitive impair-
ment, generalized action dystonia, choreoathetosis, mild 
pyramidal signs, and occasional ballistic movements. 
Self-injurious behavior included biting of hands, fingers 
and lips. The patient could not sit or walk without support. 
The neurological symptoms in this patient were combined 
with uric acid hyperproduction with hyperuricemia, an in-
creased urinary urate-to-creatinine ratio and signs of urate 
nephropathy according to ultrasound data.
Structural modeling of HPRT1 del8Val loss of  
function mutation by bioinformatic algorithms
The BLAST algorithm (NCBI) was used for the com-
parison of human and murine HPRT1 gene sequences. 
The alignment shows 98.6% nucleotide sequence homo-
logy. The primary structure of the HPRT1 protein and 
mutation locus was similar enough to be studied in Mus 
musculus.
Structural models of the HPRT1 protein and its frag-
ments (PDB) were used as templates for the M4T Rap-
torX structure prediction algorithm to obtain structural 
models of the mutation site and whole mutated protein 
with altered conformation (Kalmykov et al. 2018).
Models were visualized and aligned in PyMol (Schrö-
dinger, Portland, OR). The cooperativity of HPRT1 ho-
modimer subunits was suggested to be disrupted by the 
conformational changes observed in the predicted structu-
re of HPRT1. The deleted valine was found to be located 
in the HPRT1 monomer surface close to the homodimer 
junction.
Hindered enzymatic soma assembly may be the reason 
for the biological function loss - the HPRT1 homotetramer 
appears in its native conformation as a dimer of dimers. 
The fully functional HPRT1 complex strongly depends on 
its intermolecular surface structure (Figures 3, 4, 5).
The alignment of three native monomers with the del-
8Val HPRT1 predicted model shows that the whole pro-
tein is slightly changed, with a rotational conformational 
distribution along the chain. Accordingly, dislocated char-
ged residues are suggested to be the reason for the dime-
rization disruption.
Developing a system for gene editing
To introduce the 8Val deletion in the first exon of the 
HPRT1 gene, we used the CRISPR-Cas9 genomic editing 
system with the most successful sgRNA, the PAM site of 
which was removed at 13 bp from the place of the propo-
sed deletion. For the selection of sgRNA, we used Chop-
chop (http://chopchop.cbu.uib.no/) (Chapman et al. 2017, 
Labun et al. 2018) web utilities and Algorithms (http://
www.e-crisp.org/) (Heigwer et al. 2014). The scheme for 
introducing a deletion is shown in Figure 6. For homo-
logous recombination, after making the incision, we used 
a synthetic matrix with a deletion length of 70 bp.
The genetic construct for microinjections included a 
mixture of the vector for the expression of Cas9 and sgR-
NA (px330), as well as the matrix for homologous recom-
bination (ssODN), in a ratio of 1 part Cas9 to 3 parts of 
the ssODN matrix.
To verify the efficiency of the selected genomic editing 
system, microinjected embryos were cultured to the blas-
tocyst stage, and then the DNA from these organisms was 
isolated and amplified. A fragment of the gene of interest 
was sequenced, as described above. As shown in Figure 6, 
the selected editing system leads to a deletion in the first 
exon of the HPRT1 gene at the 8Val position.
Generation and genetic analysis of primary  
genetically modified animals
The F0 generation of a genetically modified animal mo-
del of Lesch-Nyhan syndrome was obtained by the mi-
croinjection of a solution of a genetic construct into the 
pronucleus of a fertilized egg cell and subsequent trans-
Table 2. Results of direct automatic sequencing of the entire 
coding region of the HPRT1 gene, including exon-intron bound-
aries.
Nucleotide Effect Amino acid change
c.23_25delTCG Small deletion (exon 1) p.Val8del
Table 1. Primers used to amplify a fragment of the HPRT1 gene 
of 544 b.p. in size.
Primer Sequence
Forward TGATTATCTGGGAATCCTCTGG
Reverse CATCTAGCCAGACTCCAGGAA
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plantation into the oviduct of a pseudopregnant recipient 
(Ittner and Götz 2007, Liu et al. 2013, Raveux et al. 2017, 
Richa 2001). The results of this experiment are presented 
in Table 3.
In total, 78 recipients were used, and 615 one- and two-
cell embryos were transferred at 3-5 embryos per horn of 
the uterus. We significantly reduced the number of em-
bryos transferred to an individual recipient compared to 
standard protocols (Kalmykov et al. 2018), as it was pre-
viously shown that with a decrease in the number of trans-
ferred embryos, the efficiency of transplantation increases 
(Silaeva et al. 2013).
9 recipients, we observed abortions in the later stages 
(genetic analysis of abortive material was not performed 
due to the unsuitability of the material). Of the 615 trans-
ferred embryos, 12 newborn mice were received. Seven to 
14 days after birth, all mice were sampled, the DNA was 
isolated and sequenced, and restriction analysis was per-
Table 3. The results of the generation of primary genetically modified animals to obtain a model of Lesch-Nyhan syndrome.
Used Recipients Amount of Trans-planted embryos
Amount of recipients 
giving birth
The amount of new-
born mice
Amount of genetical-
ly modified animals 
from newborns
78 615 9 12 4
Table 4. The results of experiments conducted to obtain F1 animals carrying the mutant HPRT1 gene.
Primary transgene, number Descendants of F1, amount Transgenes from these animals
565 31 1
566 8 0
567 0 0
567 21 0
Figure 3. Dimer of dimers, HPRT1 homoheterotetramer (PDB 
ID 5w8v)
Figure 5. Native conformation of the HPRT1 monomer (left 
green colored) in contact with predicted mutated rotamer (cyan) 
built by the RaptorX algorithm.
Figure 4. HPRT1 homodimer with 8Val highlighted in both 
monomers (magenta).
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formed on the obtained samples. Four of the 12 obtained 
animals were mosaic transgenes (Figure 1, a, b).
Generation and genetic analysis of F1 genetically 
modified animals
The resulting primary transgenes were assigned numbers 
565, 566, 567, and 568. Males 565, 567 and 568 were ma-
ted with females of the CBA x C57BL/6 hybrid strain, and 
female 566 was mated with a male of the CBA x C57BL/6 
hybrid strain. A total of 31 descendants of F1 were recei-
ved from mouse 565, 8 descendants of F1 were received 
from mouse 566, 21 descendants of F1 were received from 
mouse 568, and no offspring were produced from mouse 
567. All progeny obtained were analyzed using Sanger 
sequencing and restriction analysis, and one genetically 
modified F1 animal, female 2296, was identified (Fig 2, 
a, b). The results of these experiments are presented in 
Table 4. Mouse 2296 was also mated with a male from 
the CBA x C57BL/6 hybrid strain, and descendants of F2 
have already been received from this mating.
Discussion
Mutations in the HPRT1 gene can cause severe neurolo-
gical and metabolic disorders in humans (Fu et al. 2014, 
Harris 2018). It has been shown that mice carrying a de-
fective gene, as a rule, lack bright phenotypic manifesta-
tions (Bell et al. 2016). However, during the creation of 
genetically modified animals with a deletion of the nu-
cleotide triplet, which causes the absence of valine in the 
eighth position of the amino acid sequence of the protein, 
we encountered certain difficulties. First, from 615 trans-
planted embryos, only 12 were able to complete full em-
bryonic development. In addition, in 9 recipients (11.5% 
of the total), we observed abortions in the later stages. 
These data may indicate possible violations of embryo-
nic development in animals carrying a mutant copy of the 
HPRT1 gene. In addition, all of the primary transgenes 
obtained were mosaics, with a mutant gene content of less 
than 20% in the genome. Only one of the obtained pri-
mary transgenes was capable of vertical transgene trans-
mission, with a rather low probability. However, at this 
stage of the experiment, we have already obtained an F2 
generation of genetically modified animals with a muta-
ted copy of the HPRT gene.
Conclusion
In this paper, we presented the results of the development 
and production of a new genetically modified mouse line 
model for Lesch–Nyhan syndrome.
Figure 6. Scheme for introducing a deletion at the 8Val position in the first exon of the HPRT1 gene
Research Results in Pharmacology 4(4): 115–122 121
We believe that the proposed model can be successful-
ly used for basic research and preclinical testing of drugs 
for the treatment of Lesch–Nyhan syndrome.
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